GILD logo Gilead Sciences +
Gilead Sciences
+

Gilead Sciences (GILD) Business News

Track Gilead Sciences in real time with a live news feed covering Gilead Sciences stock news, official press releases, company announcements, and an archive of historical Gilead Sciences news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection

Gilead (GILD) Moves 3.3% Higher: Will This Strength Last?

Zacks Investment Research

9:26 AM | Monday | Jun 29, 2026

news photo
Loading...

Gilead (GILD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Read full article redirect
9:26 AM | Monday | Jun 29, 2026

Gilead (GILD) Moves 3.3% Higher: Will This Strength Last?

Zacks Investment Research

Gilead (GILD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Read full article arrow
News Thumbnail
11:21 AM | Thursday | Jun 25, 2026

Gilead's Breast Cancer Drug Trodelvy Wins FDA Nod for Expanded Use

Zacks Investment Research

GILD wins FDA approval to expand Trodelvy into first-line metastatic triple-negative breast cancer, opening a broader treatment opportunity.

Read full article arrow
News Thumbnail
12:25 PM | Wednesday | Jun 24, 2026

Gilead Wins EC Approval to Expand Trodelvy's Label in Metastatic TNBC

Zacks Investment Research

Gilead secures EC approval to expand Trodelvy into first-line metastatic TNBC, marking a new treatment option and broadening its oncology reach.

Read full article arrow
News Thumbnail
9:00 AM | Tuesday | Jun 23, 2026

Gilead Sciences: The Market Is Underestimating Its Growth Runway

Seeking Alpha

Gilead Sciences offers a compelling long-term value opportunity after a significant pullback, with a "Buy" rating reaffirmed. GILD's core HIV franchise drives 72% of sales, with robust growth from Biktarvy and rapid adoption of Yeztugo, now expected to reach $1 billion in annual sales. Management raised 2026 revenue growth guidance to 5.5% at midpoint, citing strong HIV performance and momentum in oncology with Trodelvy.

Read full article arrow
News Thumbnail
10:01 AM | Thursday | Jun 18, 2026

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know

Zacks Investment Research

Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Read full article arrow
News Thumbnail
12:30 PM | Wednesday | Jun 17, 2026

The Healthcare M&A Wave

Forbes

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.

Read full article arrow
News Thumbnail
3:21 PM | Tuesday | Jun 16, 2026

FDA Accepts Gilead's Filing for Weekly Oral Yeztugo for HIV Prevention

Zacks Investment Research

Gilead seeks FDA approval for once-weekly oral Yeztugo for HIV prevention, aiming to expand access with a new long-acting PrEP option.

Read full article arrow
News Thumbnail
7:01 PM | Monday | Jun 15, 2026

Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know

Zacks Investment Research

Gilead Sciences (GILD) reached $124.3 at the closing of the latest trading day, reflecting a -1.03% change compared to its last close.

Read full article arrow
News Thumbnail
4:34 PM | Monday | Jun 15, 2026

U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention

Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) for Yeztugo® (lenacapavir) 300-mg tablet as a potential once-weekly (QW) oral formulation for the prevention of HIV as pre-exposure prophylaxis (PrEP).
The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of February 2, 2027. “This filing reflects Gilead's continued commitment to advancin.

Read full article arrow
News Thumbnail
8:30 AM | Friday | Jun 12, 2026

Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief

Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Ebola--Gilead Sciences today announced a donation of more than 2,000 vials of its intravenous antiviral therapy, remdesivir, to the Republic of Uganda to support response efforts to the current outbreak of Ebola Bundibugyo virus disease (BVD). This donation, along with the additional supply being readied, continues the company's long-standing work to address emerging infectious diseases.“At Gilead, we recognize the urgency and human toll of global health emergencie.

Read full article arrow
News Thumbnail